Top PE investments in biotools in 2021
2021 was an especially active year for private equity (PE) firms. According to PitchBook, the number of deals surged over 51% last year to top 8,600. Among the beneficiaries of the 29% increase in deals were biotool firms, which supply laboratory instrumentation and aftermarket supplies for the analysis of genes, cells, and proteins (excluding in vitro diagnostics tools). Read More
Broad Sky Partners acquires Thomas Scientific
Broad Sky Partners stated a strategic investment from Capital Constellation as well as its acquisition of Thomas Scientific. Read More
CuriRx launches Advanced Bioprocessing and Analytical Center
CuriRx has launched its Advanced Bioprocessing and Analytical Center to provide end-to-end support to the developers of biotherapeutics. Read More
Purigen Biosystems announces distribution agreement in EU
Purigen Biosystems entered a new distribution agreement with the Institute of Applied Biotechnologies (IAB). Under the agreement, IAB has received exclusive rights to distribute, service, and support Purigen's automated ionic purification system and microfluidic kits in the Czech Republic, Hungary, Poland, Romania, and Slovakia. Read More
CAR T-cell therapy collaborations expand cancer treatment options
Considering the broad range of the causes of cancer and the heavy impact on patients, advanced and innovative treatments are essential to fighting it. One technology being explored for this purpose is CAR T-cell therapy, because it trains the body's immune system to specifically target cancerous cells, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard. Some healthcare institutions are collaborating with companies to develop such technologies, including Celularity, Lonza, and the Memorial Sloan Kettering Cancer Center. Read More
Excellos launches to advance cell and gene therapies
Excellos, a cell therapy contract development and manufacturing organization, has announced its official corporate launch and closing of $15 million in funding from Telegraph Hill Partners. Read More
Samsung Biologics reports Q4, 2021 fiscal year financial results
Samsung Biologics reported strong financial results for the fourth quarter and record high earnings for the 2021 fiscal year, achieving fourth quarter revenue of 444.3 billion South Korean won ($37 million U.S.), an increase of 18% from 375.3 billion South Korean won ($31 billion U.S.) reported for the fourth quarter last year. Read More
TriSalus Life Sciences announces collaboration with CU Anschutz
TriSalus Life Sciences has entered a strategic research collaboration with the University of Colorado Anschutz Medical Campus (CU Anschutz). The collaboration will leverage TriSalus' immunotherapy platform, which integrates immunotherapeutics and drug delivery technology, to address the unique challenges of treating tumors in the liver and pancreas. Read More
Colorcon Ventures invests in Apprentice
Colorcon Ventures has invested in Apprentice, a provider of intelligent manufacturing execution systems designed specifically for the life sciences industry. Apprentice offers a dynamic, end-to-end platform with software applications that are designed to streamline batch-based manufacturing and remote collaboration. Read More
64x Bio gains funding to advance cell line engineering platform
64x Bio, a synthetic biology company, announced the close of a $55 million series A financing round to fund the expansion of VectorSelect, the company's cell line engineering platform. Read More
SLAS2022 International Conference & Exhibition
February 5-9
Boston, Massachusetts United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter